Lisata finds a lifeline in Marea merger

Lisata Therapeutics announced a stock-for-stock acquisition of Marea Therapeutics on September 17, 2026, following the collapse of its planned merger with Kuva Labs.

The transaction is accompanied by a $225 million private placement backed by major life-sciences investors, including RA Capital, Forbion, Third Rock Ventures and Sofinnova Investments. The financing is expected to fund operations into 2028.

The combined company will shift away from Lisata’s oncology focus and concentrate on Marea’s cardioendocrine pipeline, including MAR001/005 for severe hypertriglyceridemia and MAR002 for acromegaly.

Marea investors are expected to own about 59.5% of the combined company, private-placement investors about 38.1%, and existing Lisata shareholders only about 2.4% on a fully diluted, as-converted basis.

Both Marea programs are in Phase 2 development, with topline data expected in the fourth quarter of 2026. Lisata’s previous Kuva transaction failed after Kuva could not secure financing; Lisata is also seeking a $2 million termination fee in related litigation.